The aims of the study were twofold: (1) to evaluate the effect of food on t
he relative oral bioavailability of topotecan gelatin capsules in patients
with solid tumours, and (2) to determine the absolute bioavailability of or
al topotecan with reference to the intravenous (i.v.) formulation. The stud
y had a randomized two-period cross-over design. On day 1 of the first trea
tment course patients were administered 2.3 mg m(-2) day(-1) of oral topote
can with or without a high-fat breakfast. They crossed over to receive the
alternate regimen on day 2. In the second course (3 weeks later) fasted pat
ients received topotecan orally (2.3 mg m(-2) day(-1)) or i.v. (1.5 mg m(-3
) day). They crossed over to receive the alternate regimen on day 2. On day
s 3-5 of both treatment courses patients received oral topotecan, Plasma ph
armacokinetics were performed on days 1 and 2 of the first and second cours
e using a high-performance liquid chromatographic assay. Eighteen patients
were enrolled in the study. The ratio of the area under the curve to infini
ty during fasted and high-fat treatment was 0.93 +/- 0.23 (90% confidence i
nterval (CI) 0.83-1.03). Maximal plasma concentrations of topotecan were si
milar after ingestion of the capsules with (10.6 +/- 4.4 ng ml(-1)) or with
out food (9.2 +/- 4.1 ng ml(-1)) (P = 0.130). The lime needed to reach maxi
mal plasma levels was significantly prolonged after food intake (median 3.1
h, range 2.8-6.1) compared to fasted conditions (2.0 h, range 1.1-8.1) (P
= 0.013). The absolute bioavailability of topotecan averaged 42 +/- 13% (90
% CI 37- 47%). The apparent terminal half-life was significantly longer aft
er administration of oral topotecan (3.9 +/- 1.0 h) than after i.v. adminis
tration (2.7 +/- 0.4 h) (P < 0.001). Topotecan demonstrates suitable bioava
ilability for oral treatment. Go-administration of the topotecan gelatin ca
psules with a high-fat breakfast leads to a small decrease in absorption ra
te but does not affect the extent of absorption.